Breaking News Headlines Today

News from pharmtech.com

All of today’s top news stories from pharmtech.com. Get the full analysis behind how media bias impacts breaking news.

Overall, we’ve indexed 135 stories from pharmtech.com over the past 3 months.

We’ve assigned a media bias rating of Center to pharmtech.com. You can read more about our methodology here.

If you want to know if pharmtech.com is credible or reliable, look no further. We rank pharmtech.com as High factuality. Find out more about our methodology here.

Information about pharmtech.com

Where is pharmtech.com located?pharmtech.com's Website

Media Bias Ratings

Average Bias Rating:

Center

byAd Fontes Media

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Tariffs & Trade Policy: What to Watch for, Cost Impacts, and Supply Chain Strategies

100% Center coverage: 1 sources

US pharma tariffs may start low and rise, risking drug shortages, higher costs, and pressure on generics amid reshoring push.Tariffs · United States See the Story

Ask the Expert: Identity Testing on a Final Product

100% Center coverage: 1 sources

In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, discuss if and when identity testing is necessary to be performed on a final product when the API is sourced from a third party.See the Story

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

100% Center coverage: 1 sources

Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.Read Article

News from pharmtech.com

News from pharmtech.com

Information about pharmtech.com

Media Bias Ratings

Factuality

Ownership

Top pharmtech.com News

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

US bans vaccine ingredient targeted by anti-vaxxers

FDA Names Former Pharmaceutical Company Executive to Oversee US Drug Program

Yellowstone's Small Earthquakes Easier to Analyze with Artificial Intelligence

EMA Approves Lower GWP Alternative for Inhalation Medicine

Interfering with Interventions in Aseptic Processing

Trade Policy Shifts: Compliance and Cost Strategies for Pharma

Drug Digest: Speed, Flexibility Top Large-Molecule Manufacturing Trends

Tariffs & Trade Policy: What to Watch for, Cost Impacts, and Supply Chain Strategies

Ask the Expert: Identity Testing on a Final Product

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

Similar News Topics

Topics Most Covered by pharmtech.com

Sources Covering Similar Topics

Breaking News Topics Related to pharmtech.com

Information about pharmtech.com

Media Bias Ratings

Factuality

Ownership

Yellowstone's Small Earthquakes Easier to Analyze with Artificial Intelligence

EMA Approves Lower GWP Alternative for Inhalation Medicine

Interfering with Interventions in Aseptic Processing

Trade Policy Shifts: Compliance and Cost Strategies for Pharma

Drug Digest: Speed, Flexibility Top Large-Molecule Manufacturing Trends

Tariffs & Trade Policy: What to Watch for, Cost Impacts, and Supply Chain Strategies

Ask the Expert: Identity Testing on a Final Product

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs